EA200702595A1 - Композиции контролируемого высвобождения в форме наночастиц, содержащие ингибитор агрегации тромбоцитов - Google Patents

Композиции контролируемого высвобождения в форме наночастиц, содержащие ингибитор агрегации тромбоцитов

Info

Publication number
EA200702595A1
EA200702595A1 EA200702595A EA200702595A EA200702595A1 EA 200702595 A1 EA200702595 A1 EA 200702595A1 EA 200702595 A EA200702595 A EA 200702595A EA 200702595 A EA200702595 A EA 200702595A EA 200702595 A1 EA200702595 A1 EA 200702595A1
Authority
EA
Eurasian Patent Office
Prior art keywords
platelet aggregation
inhibitor
nanoparticles containing
composition
compositions
Prior art date
Application number
EA200702595A
Other languages
English (en)
Russian (ru)
Inventor
Скотт Дженкинс
Гэри Ливерсидж
Пол Старк
Джон Г. Девэйн
Нилл Фэннинг
Гурвиндер Сингх Рекхи
Original Assignee
Элан Фарма Интернэшнл Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Элан Фарма Интернэшнл Лимитед filed Critical Элан Фарма Интернэшнл Лимитед
Publication of EA200702595A1 publication Critical patent/EA200702595A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EA200702595A 2005-05-23 2006-05-23 Композиции контролируемого высвобождения в форме наночастиц, содержащие ингибитор агрегации тромбоцитов EA200702595A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68362005P 2005-05-23 2005-05-23
PCT/US2006/019905 WO2008030209A2 (en) 2005-05-23 2006-05-23 Nanoparticulate and controlled release compositions comprising a platelet aggregation inhibitor

Publications (1)

Publication Number Publication Date
EA200702595A1 true EA200702595A1 (ru) 2008-12-30

Family

ID=39153748

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200702595A EA200702595A1 (ru) 2005-05-23 2006-05-23 Композиции контролируемого высвобождения в форме наночастиц, содержащие ингибитор агрегации тромбоцитов

Country Status (12)

Country Link
US (1) US20090297596A1 (enExample)
EP (1) EP1937218A2 (enExample)
JP (1) JP2008545808A (enExample)
KR (1) KR20080047509A (enExample)
CN (1) CN101287451A (enExample)
BR (1) BRPI0609982A2 (enExample)
CA (1) CA2611506A1 (enExample)
EA (1) EA200702595A1 (enExample)
IL (1) IL187567A0 (enExample)
NO (1) NO20076588L (enExample)
WO (1) WO2008030209A2 (enExample)
ZA (1) ZA200710000B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9775819B2 (en) 2009-09-16 2017-10-03 R.P. Scherer Technologies, Llc Oral solid dosage form containing nanoparticles and process of formulating the same using fish gelatin
US8779146B2 (en) 2010-04-28 2014-07-15 Nuformix Limited Cilostazol cocrystals and compositions
US9012511B2 (en) 2010-05-19 2015-04-21 Alkermes Pharma Ireland Limited Nanoparticulate cinacalcet compositions
KR101282847B1 (ko) * 2011-07-27 2013-07-05 조선대학교산학협력단 실로스타졸을 함유하는 고체분산체 및 이를 포함하는 약학 조성물
RU2015101100A (ru) * 2012-06-15 2016-08-10 Фаундейшн Фор Байомедикал Рисерч Энд Инновейшн Профилактическое и/или терапевтическое средство для умеренного когнитивного нарушения
TWI697337B (zh) 2013-08-07 2020-07-01 學校法人近畿大學 奈米粒子或奈米粒子組成物之製造方法，及支架或球囊導管之製造方法
CN103980326A (zh) * 2014-05-05 2014-08-13 珀莱雅化妆品股份有限公司 一种超临界co2反胶束萃取红景天苷的制备方法
KR101869406B1 (ko) * 2015-11-25 2018-07-24 한국유나이티드제약 주식회사 방출제어형 경질캡슐 제제
CN112592379B (zh) * 2020-12-18 2021-11-16 广东药科大学 一种β-D-葡萄糖短链脂肪酸酯化合物及其制备方法和应用
CN114796217B (zh) * 2021-01-29 2025-01-24 南京宁丹新药技术有限公司 一种含有西洛他唑的组合物在制备治疗脑血管病药物中的应用
CN117982677B (zh) * 2024-02-05 2025-09-09 沈阳药科大学 背载血小板激活抑制剂纳米粒的工程化血小板及其制备方法及应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
WO1993025190A1 (en) * 1992-06-10 1993-12-23 Eastman Kodak Company Surface modified nsaid nanoparticles
US6117455A (en) * 1994-09-30 2000-09-12 Takeda Chemical Industries, Ltd. Sustained-release microcapsule of amorphous water-soluble pharmaceutical active agent
US6143211A (en) * 1995-07-21 2000-11-07 Brown University Foundation Process for preparing microparticles through phase inversion phenomena
US6495579B1 (en) * 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
HU230454B1 (hu) * 1998-11-02 2016-07-28 Alkermes Pharma Ireland Limited Metilfenidátot tartalmazó módosított felszabadulású sokszemcsés készítmény
JP4748839B2 (ja) * 1999-03-25 2011-08-17 大塚製薬株式会社 シロスタゾール製剤
EG23951A (en) * 1999-03-25 2008-01-29 Otsuka Pharma Co Ltd Cilostazol preparation
JP4641696B2 (ja) * 1999-09-30 2011-03-02 大塚製薬株式会社 消化管下部溶解性コーティング製剤
CA2400172C (en) * 2000-02-28 2010-04-20 Genesegues, Inc. Nanocapsule encapsulation system and method
ATE419834T1 (de) * 2000-11-20 2009-01-15 Elan Pharma Int Ltd Nanopartikel bestehend aus einem arzneistoff und copolymeren von vinyl pyrrolidon und vinyl acetat als oberflächenstabilisatoren
US6573382B2 (en) * 2001-06-29 2003-06-03 Grayson Walker Stowell Polymorphic forms of 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone
CA2456806C (en) * 2001-08-08 2011-10-18 Brown University Research Foundation Methods for micronization of hydrophobic drugs
TW200301135A (en) * 2001-12-27 2003-07-01 Otsuka Maryland Res Inst Inc Pharmaceutical compositions comprising a multifunctional phosphodiesterase inhibitor and an adenosine uptake inhibitor
US8512727B2 (en) * 2003-03-03 2013-08-20 Alkermes Pharma Ireland Limited Nanoparticulate meloxicam formulations
CA2534924A1 (en) * 2003-08-08 2005-02-24 Elan Pharma International Ltd. Novel metaxalone compositions
US20050255155A1 (en) * 2004-05-11 2005-11-17 Glenmark Pharmaceuticals Limited Modified release cilostazol compositions
AU2006336417A1 (en) * 2005-05-10 2007-08-02 Elan Pharma International, Limited Nanoparticulate clopidogrel formulations
US20070003615A1 (en) * 2005-06-13 2007-01-04 Elan Pharma International Limited Nanoparticulate clopidogrel and aspirin combination formulations

Also Published As

Publication number Publication date
BRPI0609982A2 (pt) 2010-05-18
KR20080047509A (ko) 2008-05-29
IL187567A0 (en) 2011-08-01
WO2008030209A2 (en) 2008-03-13
CN101287451A (zh) 2008-10-15
JP2008545808A (ja) 2008-12-18
WO2008030209A3 (en) 2008-07-03
US20090297596A1 (en) 2009-12-03
ZA200710000B (en) 2009-12-30
CA2611506A1 (en) 2006-11-23
EP1937218A2 (en) 2008-07-02
NO20076588L (no) 2008-02-20

Similar Documents

Publication Publication Date Title
NO20073559L (no) Nanopartiklulaere tacrolimus-formuleringer
NO20076588L (no) Sammensetninger som omfatter blodplateagregeringsinhibitor i nanopartikkelform og med kontrollert frigjoring
NO20073334L (no) Nanopartikulaert benzotiofenformuleringer
NO20076692L (no) Nanopartikulaere acetaminofenformuleringer
AR063940A1 (es) Formulaciones de posaconazol nanoparticulado
JP2009531457A5 (enExample)
ATE520757T1 (de) Polykationische viskoelastische zusammensetzungen
DE602004021107D1 (de) Meloxican-formulierungen in nanoteilchenform
DE602005019336D1 (de) Zusammensetzung mit oberflächenmodifizierenden eigenschaften
GEP20125628B (en) Pharmaceutical compositions containing antagonist anti-cd40 antibody
DK1471887T3 (da) Nanopartikelkompositioner der har lysozym som overfladestabiliseringsmiddel
NO20080202L (no) Nanopartikulaere clopidogrel og aspirin kombinasjonsformuleringer
BRPI0705488A (pt) composição nanoparticulada estável, métodos de preparar a mesma e de prevenir e/ou tratar uma infecção bacteriana, composição farmacêutica, e, forma de dosagem
ATE510533T1 (de) Arzneizusammensetzungen und verfahren zum verbessern der oralen absorption von antimikrobiellen wirkstoffen
MX2015009552A (es) Composiciones que incluyen agentes para conferir caracter hidrofobico y estabilizantes y metodos para elaborar y usar los mismos.
EA201000089A1 (ru) Применение гомо- и сополимеров для стабилизации составов активных ингредиентов
ZA200901037B (en) Pyrimidone compounds as GSK-3 inhibitors
MX2019000478A (es) Composiciones de lisina: ácido clorhídrico sintético como alternativas a los ácidos convencionales en la industria de petróleo y gas.
PL373841A1 (en) Biphasic composition induced by polydextrose
MX2010009866A (es) Composiciones de inhibidores de angiogenesis en nanoparticulas.
BR112019003945A2 (pt) composições oftálmicas
EA201400666A1 (ru) Противомикробная композиция
CU23776B7 (es) Composiciones con suplemento de hierro con tolerancia mejorada
BR112017023720A2 (pt) formulações de inibidor de corrosão
EA201400664A1 (ru) Противомикробная композиция